Table 2.
Measures of D2R availability (BPND) after placebo and after MP for the RW and the SD sessions and p values for comparisons between PL and MP (repeated ANOVA)
| RW |
SD |
|||||
|---|---|---|---|---|---|---|
| PL | MP | PL versus MP | PL | MP | PL versus MP | |
| CDT | 2.43 ± 0.35 | 2.30 ± 0.35 | 0.06 | 2.48 ± 0.31 | 2.38 ± 0.31 | NS |
| PUT | 3.07 ± 0.37 | 2.81 ± 0.47 | 0.005 | 3.09 ± 0.28 | 2.85 ± 0.34 | 0.003 |
| VS | 2.95 ± 0.37* | 2.73 ± 0.41 | 0.0002 | 2.80 ± 0.37* | 2.63 ± 0.37 | 0.06 |
*p < 0.05 for the comparison of the placebo measures between the RW and SD sessions. CDT, Caudate; PUT, putamen; VS, ventral striatum; PL, placebo. Values correspond to means and standard deviations.